OBJECTIVES: Recent advances in the laboratory detection of infectious diarrhoea allow more rapid and sensitive identification of infected patients. Several commercial multiplex molecular panels are now available and may have significant advantages over culture based techniques. Faster and more sensitive testing of hospitalised patients with suspected infectious gastroenteritis could result in significant efficiencies in the utilisation of isolation facilities, however few studies have examined this potential benefit. We studied the potential clinical and cost benefits of a commercially available molecular panel. METHODS: An eight-month parallel diagnostic study was conducted to measure potential economic benefits of testing hospitalised patients with the Luminex xTAG Gastrointestinal Pathogen Panel (GPP) compared with conventional laboratory testing (based on a combination of culture, microscopy and enzyme immunoassay). Laboratory testing costs and patient isolation costs were measured or estimated for 800 patients. RESULTS: Although costing an additional £22,283, use of GPP could enable a reduction in isolation time from 2202 to 1447 days, a saving of £66,765, which more than offsets the additional laboratory testing costs. CONCLUSION: Syndromic testing of patients against a broad panel of organisms using a multiplex molecular panel can both improve detection rates and allow better laboratory workflow practices. Removing patients testing negative using this panel could result in significant patient isolation savings.
OBJECTIVES: Recent advances in the laboratory detection of infectious diarrhoea allow more rapid and sensitive identification of infectedpatients. Several commercial multiplex molecular panels are now available and may have significant advantages over culture based techniques. Faster and more sensitive testing of hospitalised patients with suspected infectious gastroenteritis could result in significant efficiencies in the utilisation of isolation facilities, however few studies have examined this potential benefit. We studied the potential clinical and cost benefits of a commercially available molecular panel. METHODS: An eight-month parallel diagnostic study was conducted to measure potential economic benefits of testing hospitalised patients with the Luminex xTAG Gastrointestinal Pathogen Panel (GPP) compared with conventional laboratory testing (based on a combination of culture, microscopy and enzyme immunoassay). Laboratory testing costs and patient isolation costs were measured or estimated for 800 patients. RESULTS: Although costing an additional £22,283, use of GPP could enable a reduction in isolation time from 2202 to 1447 days, a saving of £66,765, which more than offsets the additional laboratory testing costs. CONCLUSION: Syndromic testing of patients against a broad panel of organisms using a multiplex molecular panel can both improve detection rates and allow better laboratory workflow practices. Removing patients testing negative using this panel could result in significant patient isolation savings.
Authors: Andrej Steyer; Monika Jevšnik; Miroslav Petrovec; Marko Pokorn; Štefan Grosek; Adela Fratnik Steyer; Barbara Šoba; Tina Uršič; Tjaša Cerar Kišek; Marko Kolenc; Marija Trkov; Petra Šparl; Raja Duraisamy; W Ian Lipkin; Sara Terzić; Mojca Kolnik; Tatjana Mrvič; Amit Kapoor; Franc Strle Journal: Pediatr Infect Dis J Date: 2016-09 Impact factor: 2.129
Authors: Poornima Ramanan; Alexandra L Bryson; Matthew J Binnicker; Bobbi S Pritt; Robin Patel Journal: Clin Microbiol Rev Date: 2017-11-15 Impact factor: 26.132
Authors: Aamer Imdad; Fiona Retzer; Linda S Thomas; Marcy McMillian; Katie Garman; Peter F Rebeiro; Stephen A Deppen; John R Dunn; Amy M Woron Journal: Clin Infect Dis Date: 2018-06-01 Impact factor: 9.079